Evidence map›Paper›PMID 29609625›Full record

ArticleMalaria journal2018

PfCap380 as a marker for Plasmodium falciparum oocyst development in vivo and in vitro.

Leslie S Itsara, Yaxian Zhou, Julie Do, Samrita Dungel, Matthew E Fishbaugher, Will W Betz, Thao Nguyen, Mary Jane Navarro, Erika L Flannery, Ashley M Vaughan and 2 more

Abstract read
In one paragraph

Article in Malaria journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. PfApiAT2 is a proline transporter essential for the transmission ofbioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. OocystMeter, a machine-learning algorithm to count and measurebioRxiv : the preprint server for biology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Novel systems to study vector-pathogen interactions in malaria.Frontiers in cellular and infection microbiology · 2023
    Review
  12. Advancing Key Gaps in the Knowledge ofFrontiers in cellular and infection microbiology · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. From Genes to Transcripts, a Tightly Regulated Journey inFrontiers in cellular and infection microbiology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Leslie S ItsaraMalarVx, Inc., 307 Westlake Ave N Suite 200, Seattle, WA, 98109, USA.
Yaxian ZhouMalarVx, Inc., 307 Westlake Ave N Suite 200, Seattle, WA, 98109, USA.
Julie DoMalarVx, Inc., 307 Westlake Ave N Suite 200, Seattle, WA, 98109, USA.
Samrita DungelMalarVx, Inc., 307 Westlake Ave N Suite 200, Seattle, WA, 98109, USA.
Matthew E FishbaugherCenter for Infectious Disease Research, 307 Westlake Ave N Suite 500, Seattle, WA, 98109, USA.
Will W BetzCenter for Infectious Disease Research, 307 Westlake Ave N Suite 500, Seattle, WA, 98109, USA.
Thao NguyenCenter for Infectious Disease Research, 307 Westlake Ave N Suite 500, Seattle, WA, 98109, USA.
Mary Jane NavarroCenter for Infectious Disease Research, 307 Westlake Ave N Suite 500, Seattle, WA, 98109, USA.
Erika L FlanneryCenter for Infectious Disease Research, 307 Westlake Ave N Suite 500, Seattle, WA, 98109, USA.
Ashley M VaughanCenter for Infectious Disease Research, 307 Westlake Ave N Suite 500, Seattle, WA, 98109, USA.
Stefan H I KappeCenter for Infectious Disease Research, 307 Westlake Ave N Suite 500, Seattle, WA, 98109, USA.
Anil K GhoshMalarVx, Inc., 307 Westlake Ave N Suite 200, Seattle, WA, 98109, USA. anil.ghosh@cidresearch.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the importance of the Plasmodium berghei oocyst capsule protein (PbCap380) in parasite survival, very little is known about the orthologous Plasmodium falciparum capsule protein (PfCap380). The goal of this work was to study the growth of P. falciparum oocysts using PfCap380 as a developmental marker.

methodsTo study P. falciparum oocyst development using both in vivo (mosquito-derived) and in vitro (culture-derived) growth conditions, antibodies (polyclonal antisera) were raised against PfCap380. For studies on in vivo oocysts, mature P. falciparum gametocytes were fed to Anopheles stephensi mosquitoes. For studies on in vitro parasites, P. falciparum gametocytes were induced and matured for subsequent ookinete production. Ookinetes were purified and then tested for binding affinity to basal lamina components and transformation into early oocysts, which were grown on reconstituted basal lamia coated wells with novel oocyst media. To monitor in vivo oocyst development, immunofluorescence assays (IFA) were performed using anti-PfCap380 antisera on Pf-infected mosquito midguts. IFA were also performed on culture-derived oocysts to follow in vitro oocyst development.

resultsThe anti-PfCap380 antisera allowed detection of early midgut oocysts starting at 2 days after gametocyte infection, while circumsporozoite protein was definitively observed on day 6. For in vitro culture, significant transformation of gametocytes to ookinetes (24%) and of ookinetes to early oocysts (85%) was observed. After screening several basal lamina components, collagen IV provided greatest binding of ookinetes and transformation into early oocysts. Finally, PfCap380 expression was observed on the surface of culture-derived oocysts but not on gametocytes or ookinetes.

conclusionsThis study presents developmental monitoring of P. falciparum oocysts produced in vivo and in vitro. The anti-PfCap380 antisera serves as an important reagent for developmental studies of oocysts from the mosquito midgut and also from oocyst culture using in vitro methodology. The present data demonstrate that PfCap380 is a useful marker to follow the development and maturation of in vivo and in vitro produced oocysts as early as 2 days after zygote formation. Further in vitro studies focused on oocyst and sporozoite maturation will support the manufacturing of whole sporozoites for malaria vaccines.

Indexed as

DNA, ProtozoanGenetic MarkersHumansLimit of DetectionMalaria, FalciparumMolecular TypingOocystsParasitologyPlasmodium falciparumDNA, ProtozoanGenetic MarkersCapsuleCulturing systemMalaria vaccinesOocystOokinetePfCap380Plasmodium falciparum

Identifiers

PMID29609625
PMCPMC5880026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.